Deficiency of type I interferon contributes to Sle2-associated component lupus phenotypes

Jianwei Li, Yang Liu, Chun Xie, Jiankun Zhu, Desi Kreska, Laurence Morel, Chandra Mohan

Research output: Contribution to journalArticle

28 Citations (Scopus)

Abstract

Objective. Studies in mice and humans have implicated type I interferon (IFN-I) in the pathogenesis of lupus. Given that the locus for IFN-I is positioned within the Sle2 murine lupus susceptibility interval on chromosome 4, we undertook this study to investigate whether differences in IFN-I levels might potentially contribute to the phenotypes ascribed to this locus. Methods. IFN-I, anti-IFN-I, isotype control antibody, or phosphate buffered saline was administered to C57BL/6 and B6.Sle2 mice, and the serologic and cellular phenotypes were studied. In addition, B6.Sle2 mice were examined for structural and expression polymorphisms in the IFN-I gene. Results. In both B6.Sle2 congenic mice and C57BL/6 control mice, antibody-mediated blockade of IFN-I augmented serum autoantibody levels and boosted B1a cell numbers. Administration of IFN-I ameliorated these 2 features previously attributed to this disease locus. Importantly, compared with B6 controls, B6.Sle2 mice had reduced levels of IFN-I in their sera and cell culture supernatants, following stimulation. Although several sequence polymorphisms were noted in the Sle2 alleles of various IFN-I genes, it was not established whether any of the noted sequence variations were causally related to the observed phenotypes. Conclusion. Unexpectedly, reduction of IFN-I levels reproduced the serologic and cellular phenotypes previously associated with the Sle2 lupus susceptibility interval. Placing these findings in the context of other studies, the effect of IFN-I on systemic autoimmunity appears to be far more complex than originally perceived.

Original languageEnglish (US)
Pages (from-to)3063-3072
Number of pages10
JournalArthritis and Rheumatism
Volume52
Issue number10
DOIs
StatePublished - Oct 2005

Fingerprint

Interferon Type I
Phenotype
Congenic Mice
Chromosomes, Human, Pair 4
Antibodies
Serum
Autoimmunity
Autoantibodies
Genes
Cell Culture Techniques
Cell Count
Alleles
Phosphates

ASJC Scopus subject areas

  • Immunology
  • Rheumatology

Cite this

Li, J., Liu, Y., Xie, C., Zhu, J., Kreska, D., Morel, L., & Mohan, C. (2005). Deficiency of type I interferon contributes to Sle2-associated component lupus phenotypes. Arthritis and Rheumatism, 52(10), 3063-3072. https://doi.org/10.1002/art.21307

Deficiency of type I interferon contributes to Sle2-associated component lupus phenotypes. / Li, Jianwei; Liu, Yang; Xie, Chun; Zhu, Jiankun; Kreska, Desi; Morel, Laurence; Mohan, Chandra.

In: Arthritis and Rheumatism, Vol. 52, No. 10, 10.2005, p. 3063-3072.

Research output: Contribution to journalArticle

Li, J, Liu, Y, Xie, C, Zhu, J, Kreska, D, Morel, L & Mohan, C 2005, 'Deficiency of type I interferon contributes to Sle2-associated component lupus phenotypes', Arthritis and Rheumatism, vol. 52, no. 10, pp. 3063-3072. https://doi.org/10.1002/art.21307
Li, Jianwei ; Liu, Yang ; Xie, Chun ; Zhu, Jiankun ; Kreska, Desi ; Morel, Laurence ; Mohan, Chandra. / Deficiency of type I interferon contributes to Sle2-associated component lupus phenotypes. In: Arthritis and Rheumatism. 2005 ; Vol. 52, No. 10. pp. 3063-3072.
@article{6f1eea9471ce45019f6e56b22ac68fd6,
title = "Deficiency of type I interferon contributes to Sle2-associated component lupus phenotypes",
abstract = "Objective. Studies in mice and humans have implicated type I interferon (IFN-I) in the pathogenesis of lupus. Given that the locus for IFN-I is positioned within the Sle2 murine lupus susceptibility interval on chromosome 4, we undertook this study to investigate whether differences in IFN-I levels might potentially contribute to the phenotypes ascribed to this locus. Methods. IFN-I, anti-IFN-I, isotype control antibody, or phosphate buffered saline was administered to C57BL/6 and B6.Sle2 mice, and the serologic and cellular phenotypes were studied. In addition, B6.Sle2 mice were examined for structural and expression polymorphisms in the IFN-I gene. Results. In both B6.Sle2 congenic mice and C57BL/6 control mice, antibody-mediated blockade of IFN-I augmented serum autoantibody levels and boosted B1a cell numbers. Administration of IFN-I ameliorated these 2 features previously attributed to this disease locus. Importantly, compared with B6 controls, B6.Sle2 mice had reduced levels of IFN-I in their sera and cell culture supernatants, following stimulation. Although several sequence polymorphisms were noted in the Sle2 alleles of various IFN-I genes, it was not established whether any of the noted sequence variations were causally related to the observed phenotypes. Conclusion. Unexpectedly, reduction of IFN-I levels reproduced the serologic and cellular phenotypes previously associated with the Sle2 lupus susceptibility interval. Placing these findings in the context of other studies, the effect of IFN-I on systemic autoimmunity appears to be far more complex than originally perceived.",
author = "Jianwei Li and Yang Liu and Chun Xie and Jiankun Zhu and Desi Kreska and Laurence Morel and Chandra Mohan",
year = "2005",
month = "10",
doi = "10.1002/art.21307",
language = "English (US)",
volume = "52",
pages = "3063--3072",
journal = "Arthritis and Rheumatology",
issn = "2326-5191",
publisher = "John Wiley and Sons Ltd",
number = "10",

}

TY - JOUR

T1 - Deficiency of type I interferon contributes to Sle2-associated component lupus phenotypes

AU - Li, Jianwei

AU - Liu, Yang

AU - Xie, Chun

AU - Zhu, Jiankun

AU - Kreska, Desi

AU - Morel, Laurence

AU - Mohan, Chandra

PY - 2005/10

Y1 - 2005/10

N2 - Objective. Studies in mice and humans have implicated type I interferon (IFN-I) in the pathogenesis of lupus. Given that the locus for IFN-I is positioned within the Sle2 murine lupus susceptibility interval on chromosome 4, we undertook this study to investigate whether differences in IFN-I levels might potentially contribute to the phenotypes ascribed to this locus. Methods. IFN-I, anti-IFN-I, isotype control antibody, or phosphate buffered saline was administered to C57BL/6 and B6.Sle2 mice, and the serologic and cellular phenotypes were studied. In addition, B6.Sle2 mice were examined for structural and expression polymorphisms in the IFN-I gene. Results. In both B6.Sle2 congenic mice and C57BL/6 control mice, antibody-mediated blockade of IFN-I augmented serum autoantibody levels and boosted B1a cell numbers. Administration of IFN-I ameliorated these 2 features previously attributed to this disease locus. Importantly, compared with B6 controls, B6.Sle2 mice had reduced levels of IFN-I in their sera and cell culture supernatants, following stimulation. Although several sequence polymorphisms were noted in the Sle2 alleles of various IFN-I genes, it was not established whether any of the noted sequence variations were causally related to the observed phenotypes. Conclusion. Unexpectedly, reduction of IFN-I levels reproduced the serologic and cellular phenotypes previously associated with the Sle2 lupus susceptibility interval. Placing these findings in the context of other studies, the effect of IFN-I on systemic autoimmunity appears to be far more complex than originally perceived.

AB - Objective. Studies in mice and humans have implicated type I interferon (IFN-I) in the pathogenesis of lupus. Given that the locus for IFN-I is positioned within the Sle2 murine lupus susceptibility interval on chromosome 4, we undertook this study to investigate whether differences in IFN-I levels might potentially contribute to the phenotypes ascribed to this locus. Methods. IFN-I, anti-IFN-I, isotype control antibody, or phosphate buffered saline was administered to C57BL/6 and B6.Sle2 mice, and the serologic and cellular phenotypes were studied. In addition, B6.Sle2 mice were examined for structural and expression polymorphisms in the IFN-I gene. Results. In both B6.Sle2 congenic mice and C57BL/6 control mice, antibody-mediated blockade of IFN-I augmented serum autoantibody levels and boosted B1a cell numbers. Administration of IFN-I ameliorated these 2 features previously attributed to this disease locus. Importantly, compared with B6 controls, B6.Sle2 mice had reduced levels of IFN-I in their sera and cell culture supernatants, following stimulation. Although several sequence polymorphisms were noted in the Sle2 alleles of various IFN-I genes, it was not established whether any of the noted sequence variations were causally related to the observed phenotypes. Conclusion. Unexpectedly, reduction of IFN-I levels reproduced the serologic and cellular phenotypes previously associated with the Sle2 lupus susceptibility interval. Placing these findings in the context of other studies, the effect of IFN-I on systemic autoimmunity appears to be far more complex than originally perceived.

UR - http://www.scopus.com/inward/record.url?scp=26844573357&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=26844573357&partnerID=8YFLogxK

U2 - 10.1002/art.21307

DO - 10.1002/art.21307

M3 - Article

C2 - 16200585

AN - SCOPUS:26844573357

VL - 52

SP - 3063

EP - 3072

JO - Arthritis and Rheumatology

JF - Arthritis and Rheumatology

SN - 2326-5191

IS - 10

ER -